Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cassava Sciences Inc SAVA

Healthcare
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

Recent & Breaking News (NDAQ:SAVA)

Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer

GlobeNewswire January 4, 2021

USAN Modifies Lead Drug Candidate's Chemical Name to 'Simufilam'

GlobeNewswire November 27, 2020

Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock

GlobeNewswire November 13, 2020

Cassava Sciences Announces Proposed Public Offering of Common Stock

GlobeNewswire November 12, 2020

Cassava Sciences Reports Third Quarter 2020 Financial Results

GlobeNewswire November 9, 2020

Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer's Disease

GlobeNewswire November 4, 2020

Cassava Sciences' Phase 2b Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2020

GlobeNewswire September 30, 2020

Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer's Disease

GlobeNewswire September 14, 2020

Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET

GlobeNewswire September 11, 2020

Cassava Sciences to Present at H.C. Wainwright's 22nd Annual Global Investment Conference

GlobeNewswire September 9, 2020

Cassava Sciences Announces New Patent Grant

GlobeNewswire September 3, 2020

Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name 'sumifilam' by USAN

GlobeNewswire August 24, 2020

Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review

GlobeNewswire August 12, 2020

Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference

GlobeNewswire July 9, 2020

Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update

GlobeNewswire June 16, 2020

Cassava Sciences Announces Presentation at the Jefferies Virtual Healthcare Conference and Provides Updates Regarding Phase 2b Study of PTI-125

GlobeNewswire June 3, 2020

Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer's Disease Does Not Meet Primary Endpoint

GlobeNewswire May 15, 2020

Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire May 6, 2020

Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health

GlobeNewswire April 23, 2020

Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020

GlobeNewswire March 26, 2020